349 related articles for article (PubMed ID: 23147197)
41. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
42. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic cancer therapies: DNA methyltransferase inhibitors.
Strathdee G; Brown R
Expert Opin Investig Drugs; 2002 Jun; 11(6):747-54. PubMed ID: 12036419
[TBL] [Abstract][Full Text] [Related]
44. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
45. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
Jankowska AM; Millward CL; Caldwell CW
Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
[TBL] [Abstract][Full Text] [Related]
46. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract][Full Text] [Related]
47. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
McAnulty J; DiFeo A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322239
[No Abstract] [Full Text] [Related]
48. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
49. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
50. Targeting GLI Transcription Factors in Cancer.
Didiasova M; Schaefer L; Wygrecka M
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695137
[TBL] [Abstract][Full Text] [Related]
51. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy.
Komar D; Juszczynski P
Clin Epigenetics; 2020 Oct; 12(1):147. PubMed ID: 33054831
[TBL] [Abstract][Full Text] [Related]
52. Role of Drug-metabolizing Enzymes in Cancer and Cancer Therapy.
Feng S; Li A; Zheng YC; Liu HM
Curr Drug Metab; 2020; 21(1):67-76. PubMed ID: 31902352
[TBL] [Abstract][Full Text] [Related]
53. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
Santhosh S; Kumar P; Ramprasad V; Chaudhuri A
Future Oncol; 2015; 11(2):279-93. PubMed ID: 25591839
[TBL] [Abstract][Full Text] [Related]
54. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
55. The path to oncology drug target validation: an industry perspective.
Cortés-Cros M; Schmelzle T; Stucke VM; Hofmann F
Methods Mol Biol; 2013; 986():3-13. PubMed ID: 23436402
[TBL] [Abstract][Full Text] [Related]
56. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
Wooten DJ; Quaranta V
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
[TBL] [Abstract][Full Text] [Related]
57. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
58. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling.
Evelyn CR; Wade SM; Wang Q; Wu M; Iñiguez-Lluhí JA; Merajver SD; Neubig RR
Mol Cancer Ther; 2007 Aug; 6(8):2249-60. PubMed ID: 17699722
[TBL] [Abstract][Full Text] [Related]
59. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
60. Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M; Katoh M
Int J Mol Med; 2020 Feb; 45(2):279-297. PubMed ID: 31894255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
